Author
By Ryan Abbott Government regulation of off-label promotion by pharmaceutical companies is now an important First Amendment issue. The Food and Drug Administration (FDA) has historically restricted truthful and non-misleading speech by pharmaceutical companies under…
By Ryan Abbott Actavis is back in the spotlight regarding its allegedly anticompetitive behavior. Last month, the U.S. District Court for the Southern District of New York issued an injunction against Actavis and its subsidiary, Forest…
By Ryan Abbott Video: Here. On January 13, 2014 the Southwestern Law School Federalist Society student chapter hosted a debate about the FDA’s role in regulating off-label drug use featuring Professor Richard Epstein, the Laurence…
By Ryan Abbott Historically, death has been a very simple and intuitive thing to understand – it occurs when someone stops breathing and their heart stops. Visually, it is a dramatic change that anyone can…
By Ryan Abbott Last month the US Supreme Court rendered its decision on the reverse payments question. The Court held in Federal Trade Commission v. Actavis, Inc. that reverse payment settlements in patent infringement litigation…
By Ryan Abbott Justice Scalia filed an opinion concurring in part and concurring in the judgment of the Myriad decision. “I join the judgment of the Court, and all of its opinion except Part I–A…
By Ryan Abbott While awaiting the torrent of academic commentary on this case that is no doubt forthcoming, for now I thought I’d highlight a few interesting aspects of today’s unanimous Supreme Court decision in…
By Ryan Abbott The Indian Federal Department of Pharmaceuticals has released a new Drugs (Prices Control) Order that expands the list of “essential” drugs subject to government price control. Currently, a 1995 order restricts prices…
By Ryan Abbott I read an article recently which stated that the federal government is making a 51 billion dollar profit this year from student loan borrowers. That’s more annual profit than any private American…
By Ryan Abbott A few days ago, a group of more than 100 experts in chronic myeloid leukemia (CML) published an article in the medical journal Blood to draw attention to the prices of anti-cancer drugs…
